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Although idiopathic hypercalciuria (IH) is associated with
reduced bone mineral density (BMD), no studies to date have
identified predictors of BMD change over an extended period
of observation. We have studied change in femoral neck and
spine BMD z-scores in men and women with IH and stone
disease (IHSF) and their first-degree relatives in order to
determine the predictive value of commonly made clinical
measurements. Urine calcium excretion was inversely
correlated with change in femoral neck z-score over 3 years,
and marginally correlated with fall in spine z-score. Markers
of bone turnover, serum calcitriol, and urine measurements
of acid–base balance such as ammonium and sulfate had
no predictive value, nor did calcium intake assessed using
a well-established questionnaire. It would appear that
IHSF with the highest 24-h urine calcium excretion rates
are at highest risk for loss of femoral neck bone mineral over
a 3-year period.
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Reduced bone mineral density (BMD) is a common finding
in calcium stone forming (SF) patients with idiopathic
hypercalciuria (IH; IHSF).1–6 In addition to low BMD,
epidemiologic studies have shown higher fracture rates in SF
compared to control populations, particularly in males.7,8 It
has been proposed that restricted dietary calcium intake in
the face of increased renal loss of calcium contributes to
osteopenia.2 Other factors such as high salt and protein
intake,1 and hypophosphatemia9 among others have been
proposed as potential factors in the bone loss. Even though
IH is associated with bone disease, it is not possible to predict
which IHSF are at risk to develop it.
We have studied femoral neck and spine z-scores in a
cohort of IHSF and their first-degree relatives.10 Among the
IHSF, we found that z-scores varied inversely with urine
calcium loss and urine ammonium excretion. Their non-SF
relatives showed no such relationships. The difference
between the two groups appeared to reflect a lower calcium
intake among those with stones.
We have had the opportunity to re-measure femoral neck
and spine BMD of most of this cohort in order to ascertain
which, if any, of our baseline measurements was predictive of
changes in BMD over a period of 3 years. Here we present
evidence that loss of BMD, especially in the femoral neck, was
proportional to urine calcium loss at the initial evaluation,
but not strongly dependent on calcium intake, ammonium
excretion, bone turnover markers, or whether or not the
subjects formed stones. We also found that initial serum
calcitriol levels were predictive of higher subsequent z-scores,
but with much weaker effect than urine calcium itself. This is
the first evidence that urine calcium excretion, per se, predicts
changes in BMD in patients with IH.
RESULTS
Univariate analysis
Mean z-scores for the femoral neck and spine, respectively,
were 0.08 and 0.04 at the initial measurement and 0.12 and
0.24 at the time of follow-up measurement (P¼NS vs 0).
The mean changes in femoral neck and spine z-scores were
0.12 and 0.11, respectively (P¼NS vs 0).
The follow-up femoral neck z-score was not correlated
with the initial 24-h urine calcium excretion (r¼0.19,
P¼ 0.26). However, the change in femoral neck z-score
(Figure 1, left panel) was inversely correlated with the initial
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2006 International Society of Nephrology
Received 3 May 2006; revised 28 June 2006; accepted 5 July 2006;
published online 30 August 2006
Correspondence: JR Asplin, Litholink Corporation, University of Chicago
2250 W. Campbell Park Drive, Chicago, Illinois 60612, USA.
E-mail: jasplin@litholink.com
Kidney International (2006) 70, 1463–1467 1463
urine calcium (r¼0.37, P¼ 0.02) and weakly correlated
with n terminal telopeptides of type 1 collagen (r¼ 0.29,
P¼ 0.08). Follow-up spine z-score showed no significant
correlation with urine calcium (r¼0.17, P¼ 0.3), whereas
the change in spine z-score (Figure 1, right panel) showed a
weak correlation with urine calcium (r¼0.28, P¼ 0.08).
Follow-up spine z-score is correlated with dietary calcium
intake (r¼ 0.50, P¼ 0.001) due to the fact that follow-up
spine z-score is strongly correlated with initial spine z-score
and the initial spine z-score was strongly correlated with diet
calcium intake. The change in spine z-score was not
correlated (r¼ 0.12, P¼ 0.46) to diet calcium intake.
Changes in femoral neck and spine z-scores were strongly
correlated with one another (Figure 2) and points from stone
formers (dark circles) and non-stone formers (open circles)
overlap entirely (r¼ 0.63, Po0.001; coefficient¼ 0.72, 95%
CI 0.45–0.99). The intercept of the regression did not differ
from zero.
Multivariate analysis
Using a general linear model, final femoral neck z-scores
varied strongly with the initial z-score (r¼ 0.86, Po0.001),
inversely with 24-h urine calcium (P¼ 0.004) and directly
with serum calcitriol levels (P¼ 0.01). As expected, the
change in femoral neck z-score varied inversely with calcium
excretion and directly with serum calcitriol levels (P¼ 0.002
and 0.015, respectively). The follow-up spine z-score in a
multivariate linear model varied strongly with the initial
value and inversely to urine calcium excretion (P¼ 0.05) as
did change in spine z-score (P¼ 0.04). Inclusion of the drug
code in the general linear models (Materials and Methods)
did not affect the results, and the P-value for the drug code
was not significant. Inclusion of a code to denote whether the
initial and final BMD were measured at the same or at
different facilities did not affect the results and the P-value for
this code was not significant.
DISCUSSION
Our overall and main finding is that changes over 3 years in
femoral neck z-score and to a lesser extent in spine z-score
can be predicted by the 24-h urine calcium excretion in
hypercalciuric SF patients and their first-degree relatives. On
the one hand, this finding offers physicians a guide that could
be of potential prognostic value and that might possibly
influence aspects of treatment. On the other hand, the strong
predictive character of urine calcium excretion bolsters the
idea that bone mineral changes in IH are indeed linked
closely with hypercalciuria itself through mechanisms that
are yet to be properly determined.
Femoral neck z-score
On average z-score did not fall over 3 years. However, those
subjects whose femoral neck z-score did fall were primarily
those with hypercalciuria, whereas the z-score tended to rise
among those without hypercalciuria (illustrated in Figure 1,
left panel). As a result, we find a strong inverse correlation
between either change in z-score or final z-score adjusted for
the initial z-score and urine calcium excretion. We conclude
from this that urine calcium excretion, by itself, has a
predictive value concerning what will happen, to at least
femoral neck z-score, over a 3-year period. Serum calcitriol
had a lesser but significant predictive value for femoral neck
z-score. Gender, classification as a stone former or not, diet
calcium intake as assessed by a well-validated questionnaire,
and a cluster of bone turnover markers had no predictive
value. For clinical estimates using only urine calcium, the
simple linear regression coefficients can be used predictively:
change in femoral neck z-score per 3 years¼ 0.56–0.002*
urine calcium (mg/day), r¼ 0.44, Po0.001.
Spine z-score
Like femoral neck z-score, change in spine z-score was inverse
to urine calcium, but the effect is very weak. We do not have
an explanation for this disparity, especially because changes
in femoral neck and spine z-score were well correlated and
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Figure 1 | Relationship between change in z-score and urine
calcium excretion. Change in femoral neck z-score over 3 years was
inversely correlated (r¼0.37, P¼ 0.02) with initial urine calcium
excretion (left panel); change in spine z-score was also inversely
correlated (r¼0.28, P¼ 0.08) with urine calcium excretion (right
panel), but the relationship was weaker. Ellipses of containment
are 1 s.d.
Change in spine z - score



















Figure 2 | Relationship between change in femoral neck and
spine z-score over 3 years. Change in femoral neck z-score
(y axis) correlated (r¼ 0.63, Po0.001) strongly with change in spine
z-score (x axis) among IHSF (*) and their non-SF relatives (J).
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generally bone turnover is higher in spine than femoral neck
due to the higher content of trabecular bone. Initial scores at
both sites did not deviate significantly from zero, which
excludes some disparity of initial bone disease. Perhaps,
something about the biology of IH specifically affects the
femoral neck.
Effects of treatment
Even though 11 of our 47 subjects were receiving one or
more medications with a known effect on bone mineral
balance, we were unable to detect any influence of drug
use in our multivariate models. Probably this reflects the
variable and sparse conditions of treatment. Whether or
not our results can be applied to patients taking any one
specific drug cannot be determined from the experiment
presented here.
Differences from our prior study
In our initial analysis, we found significant differences
between SFs and their non-SF family members. The z-scores
of SFs inversely correlated with urine calcium and urine
ammonium, but this correlation did not exist for the non-
SFs. However, in the current study there was no difference
between SFs and non-SFs both groups showed an inverse
correlation of the follow-up BMD and the change in BMD to
calcium excretion, but no relation to urine ammonium
or other markers of renal acid excretion. In addition, there
was no effect of diet calcium intake on change in BMD,
although there was an effect of diet calcium on the initial
BMD of SFs.
Comparison to past work
One other study evaluated change in BMD over time in SF.
Cvijetic et al.11 studied 34 male recurrent SF, nine of whom
were hypercalciuric, and compared them to 30 normal male
subjects. In this study, BMD was measured by dual-energy
X-ray absorptiometry scan at the hip and spine at baseline
and 1 year later. The authors did not find a significant
difference between changes in BMD in the SF compared to
the controls. They did find significant correlations between
loss of BMD at the femoral neck and diet calcium intake,
urinary uric acid excretion, and age of the subjects. Only
serum procollagen correlated with loss of BMD at the spine.
Other bone markers such as serum osteocalcin, telopeptide,
and urine hydroxyproline showed no correlation with change
in BMD, just as we have found in our study. Of note, no
correlation was found between urine calcium excretion and
the change in BMD. We cannot explain the marked difference
between our results and theirs, other than the small number
of hypercalciuric subjects in the study and the relatively
shorter duration.
Additionally, two studies have observed the effect of
potassium citrate therapy on bone loss among SF. Pak et al.12
studied a group of 21 subjects who had kidney stones and
were taking potassium citrate. They were able to analyze
spine BMD data from both before treatment and after
treatment (mean duration 44 months). They found that
spine z-score increased significantly. In a different study,
Vescini et al.13 observed 109 subjects in a longitudinal study
where BMD of the distal radius was measured at baseline and
then 2 years after subjects had been treated with potassium
citrate. They found that after 2 years of treatment, the BMD
of the distal radius significantly increased. However, neither
study included a control arm and therefore make it difficult
to compare to our study.
Bone markers
We are surprised that markers of bone turnover had no
predictive value concerning changes in bone mineral over a
3-year period. Others have found conflicting results for
correlations between BMD and bone markers in similar
populations.
Bone-specific alkaline phosphatase. Borgi et al.,6 in a
subset of 22 subjects classified after a low calcium diet,
found that bone-specific alkaline phosphatase (BAP) was
higher in diet-independent hypercalciuric subjects compared
to controls, but no correlation was found between BMD and
BAP measurements. However, Bataille et al.5 found no
significant difference in BAP between hypercalciuric subjects
(classified after a low calcium diet as well) and controls;
Steiniche et al.14 had the same findings as Bataille, although
they did not classify hypercalciuric subjects based on a low
calcium diet. Still another study, performed by Tasca et al.,3
when classifying subjects based on fasting or absorptive
hypercalciuria, found BAP was higher among fasting
hypercalciuric subjects than controls, but found comparable
levels when comparing absorptive hypercalciuric subjects and
controls.
Hydroxyproline. Bataille et al.5 found higher hydroxypro-
line (OHP) in IH vs controls, but vertebral BMD did not
correlate with the level of OHP. Both Tasca et al.3 and Gianni
et al.4 found higher OHP levels in IH vs controls under
normal dietary conditions. Additionally, they measured OHP
after a low calcium diet; they also found that the change in
urine OHP of fasting hypercalciuric subjects was inversely
correlated with spine and femoral BMD. Cvijetic et al.11 also
found higher OHP in IH subjects than controls, and Jaeger
et al.15 found no difference in OHP between IH and normal.
Collagen breakdown products. Jaeger et al.15 found no
differences between IH and non-IHSF, but did find a negative
correlation between 24-h pyridinoline excretion and BMD.
Freundlich et al.16 found no difference of urine pyridinolines
and deoxypyridinolines between IH and control children;
similarly, Cvijetic et al.11 did not find higher mean
telopeptide levels in IH vs controls.
Summary of bone marker results. We must conclude that
available bone markers, including BAP, OHP, and collagen
breakdown products, are not useful in predicting the natural
history of this disease howsoever much they may be
abnormal in patients who have it. We must also conclude
that results have been variable between studies although one
gets the impression that higher turnover marker levels were
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more common in IH than normal. Perhaps, the turnover rate
in hypercalciuria is not as high as in diseases such as post-
menopausal osteoporosis17 or the turnover rate does not play
as critical role in creating a loss of bone mineral. This whole
area deserves more research than it has had to date. Certainly
in our work available markers were not informative.
Conclusion
In this prospective study of families of IHSF, higher 24-h
urine calcium excretion appears to be a risk factor for
increased BMD loss over time. No other marker measured at
entry into the study provided insight into which patients
would lose bone mineral. Early identification of those SF at
greatest risk of bone loss may provide greater incentive for
the treating physician to monitor bone mineral over time and
provide dietary and pharmacologic intervention as needed.
However, more studies are needed to provide even longer
term follow-up of these patients as well to provide details




Of our initial cohort of 59 subjects (30 women) from 11 families, we
have obtained new measurements of the femoral neck and spine
BMD for 47 subjects (mean age was 50715 years), of which 26 were
women. Femoral neck BMD was available for only 46 due to
technical reasons. Families were identified via IHSF probands who
had urine metabolic studies performed by Litholink Corporation
(Chicago, IL, USA). Because families were recruited from diverse
regions of the United States, multiple BMD scanning facilities were
necessary for the initial and follow-up scans. For the follow-up
work, we contacted all possible subjects and arranged subsequent
BMD measurements. Of the 12 subjects who did not participate in
the second phase of the study: one subject had died, two subjects
were too heavy to have a dual-energy X-ray absorptiometry scan,
and nine were lost to follow-up. Thirty-six of the 47 subjects had
BMD measured at the same facility that performed the initial
measurement. The average time between BMD measurements was
2.970.2 years.
Each subject was interviewed by telephone and questioned
concerning the following classes of medications: thiazide diuretics,
statins, corticosteroids, bisphosphonates, hormone replacement
therapy, calcium supplements, and alkali therapy. The process of
the interview was to inquire concerning all drugs in use whenever,
which were then classified as noted above by one of us. Of the 47
patients, 11 were taking medications: thiazide (three), bisphos-
phonate (four), estrogen (one), calcium supplement (one), statins
(five), alkali (one), or corticosteroids (two). Some patients were
taking multiple drugs.
Measurements performed at time of initial dual-energy X-ray
absorptiometry scan
Measurements performed at the time of the original BMD scan10
included 24-h urine volume, pH, calcium, phosphorus, magnesium,
sodium, potassium, chloride, urea nitrogen, sulfate, ammonium,
uric acid, oxalate, citrate, and creatinine. Bone markers included
serum BAP, serum C- and N-terminal telopeptides of type 1
collagen, and urine pyridinolines and deoxypyridinolines. In
addition, a dietary history was obtained using a semiquantitative
food frequency questionnaire18 and serum calcitriol was measured.
Analysis
T-tests were used to assess the significance of change in z-scores.
Simple correlation was used to identify initial measurements that
correlated with subsequent change in z-scores at the femoral neck
and spine. Multivariable linear models were constructed using both
change in z-score as dependent variable, and follow-up z-score with
the initial corresponding z-score as co-variate. In an exploratory
analysis, we modeled the change in z-score and follow-up z-score
adjusted for initial z-score using all initial measurements that had
significant univariate correlations; measurements were stepped in or
out of the model depending on their F-values. From this we
identified the initial measurements that had significant independent
co-variance with the z-score of interest. Data are presented as
mean7s.e.m.
To handle the drug information, we followed a simple
convention: use of thiazide, bisphosphonate, hormone replacement,
alkali, calcium supplement, or statin was coded as ‘1’, use of
corticosteroids as ‘1’ and use of none as ‘0’.
A code was created to denote whether BMD had been measured
at the same or different facilities on the two occasions. This code was
used in multivariable models.
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